March 18, 2019 10:05 AM EDT

Biohaven is betting hundreds of millions it can hustle ahead of rivals in a blockbuster race. A quick M&A deal could pay off backers big time

Biohaven $BHVN may not have anything like the market caps of its rivals at Allergan $AGN and Eli Lilly $LLY, but they’re not letting the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bio­haven is bet­ting hun­dreds of mil­lions it can hus­tle ahead of ri­vals in a block­buster race. A quick M&A deal could pay off back­ers big time